home / stock / apto / apto news

APTO News and Press, Aptose Biosciences Inc. From 01/31/24

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APTO
Market: NASDAQ
Website: aptose.com
Menu
APTO APTO Quote APTO Short APTO News APTO Articles APTO Message Board
Get APTO Alerts

News, Short Squeeze, Breakout and More Instantly...
APTO - Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancie...
APTO - Aptose Biosciences prices 4.9M shares at $1.71 in underwritten public offering

2024-01-26 10:24:21 ET More on Aptose Biosciences Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosci...

APTO - Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, t...

APTO - Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination Active Across Broad P...
APTO - Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers

2023-12-04 10:02:05 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers

APTO - Aptose Biosciences files to sell ordinary shares, warrants

2023-12-04 06:38:44 ET More on Aptose Biosciences Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data for Aptose Biosciences Financial information for Aptose Biosci...

APTO - Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
APTO - Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

2023-11-09 19:22:08 ET Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Conference Call November 09, 2023 05:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & ...

APTO - Aptose Biosciences GAAP EPS of -$1.76 beats by $0.22

2023-11-09 16:51:06 ET Aptose Biosciences press release ( NASDAQ: APTO ): Q3 GAAP EPS of -$1.76 beats by $0.22 . Total cash and cash equivalents and investments as of September 30, 2023, were $17.7 million. Expects that cash on hand and available capital to fund pl...

APTO - Aptose Reports Results for the Third Quarter 2023

Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance Mechanisms TUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Trea...
Previous 10 Next 10